---
title: "New Drug Pricing Policy Empowers Innovation; Overseas Licensing Accelerates Dual-Drive Mechanism for the Industry"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283061998.md"
description: "The General Office of the State Council issued new policies aimed at improving the drug pricing mechanism and promoting pharmaceutical innovation. Overseas licensing of domestic innovative drugs continues to grow, with Haisco signing an exclusive licensing agreement with AbbVie worth up to $745 million. Since the beginning of 2026, multiple domestic pharmaceutical companies have reached cooperation agreements with multinational giants, leading to a surge in deal volume and rising transaction values. The industry is shifting from being driven solely by overseas expansion to a dual-drive model involving both domestic and international markets, enhancing sales expectations for innovative drugs, optimizing profit margins across the industrial chain, and strengthening R&D demand"
datetime: "2026-04-16T22:59:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283061998.md)
  - [en](https://longbridge.com/en/news/283061998.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283061998.md)
---

# New Drug Pricing Policy Empowers Innovation; Overseas Licensing Accelerates Dual-Drive Mechanism for the Industry

Recently, the General Office of the State Council issued "Several Opinions on Improving the Drug Price Formation Mechanism," providing top-level design support for pharmaceutical innovation. At the same time, overseas licensing of domestic innovative drugs continues to flourish across multiple fronts. Recently, Haisco signed an exclusive licensing agreement with U.S.-based AbbVie, with a total transaction value reaching up to $745 million.

Since the start of 2026, several domestic pharmaceutical companies, including Shiyao Group and Innovent Biologics, have successively entered into overseas licensing collaborations with multinational giants. Deal volumes are surging, and transaction amounts continue to climb.

Industry experts believe that peak sales expectations for domestic innovative drugs will be significantly boosted, greatly stimulating corporate enthusiasm. The entire industry is evolving from a previously overseas-driven model to a dual-drive system encompassing both domestic and international markets, further enhancing sector confidence and predictability. On one hand, this will optimize profit margins across all stages of the domestically-oriented innovative drug supply chain. On the other hand, it will further stimulate domestic R&D demand for innovative drugs. (China Securities Journal)

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks](https://longbridge.com/en/news/282939130.md)
- [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md)
- [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md)
- [Cutia Therapeutics’ Botox Rival Meets Phase III Goals in China](https://longbridge.com/en/news/282464943.md)
- [Fusen Pharmaceutical Wins China Approval for Glucosamine Osteoarthritis Capsule](https://longbridge.com/en/news/283163403.md)